16 reports

  • 2.3 Symptoms
  • Gastric Cancer, Stage Grouping

It is also used when a patient presents certain risk factors for gastric cancer, such as genetic or familial factors (ACS, 2014).

  • Gastric Cancer
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group

" Originally, targeted therapy' s mechanism was to target the key genetic abnormality.

  • Gastric Cancer
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Gastric cancer

4546 5000 3864
  • INDIVIDUALS WITH A FAMILY HISTORY OF GASTRIC CANCER ARE AT GREATER RISK OF DEVELOPING THE DISEASE

The most important gastric cancer genetic susceptibility lies in inherited loss-of-function mutations of the tumor suppressor gene CDH##.

  • Gastric Cancer
  • East Asia
  • Japan
  • United States
  • Eli Lilly & Co.

" Originally, targeted therapy' s mechanism was to target the key genetic abnormality.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

" Originally, targeted therapy' s mechanism was to target the key genetic abnormality.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

" Originally, targeted therapy' s mechanism was to target the key genetic abnormality.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

" Originally, targeted therapy' s mechanism was to target the key genetic abnormality.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • T-001 - DRUG PROFILE
  • AMBRX INC

The presentation is entitled as Genetically Engineered NY-ESO-## Specific T-Cells in HLA-A##+ Patients with Advanced Cancers".

  • Gastric Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative
  • T-001 - DRUG PROFILE
  • GASTRIC CANCER - PIPELINE BY MERUS NV, H1 2018

The presentation is entitled as Genetically Engineered NY-ESO-## Specific T-Cells in HLA-A##+ Patients with Advanced Cancers".

  • Gastric Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative

Some of the genetic abnormalities in cancer cells may be targeted by these new drugs that are under development.

  • Gastric Cancer
  • Pharmaceutical
  • Singapore
  • United States
  • ASLAN Pharmaceuticals Pte Ltd.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Gastric Cancer
  • Lung Cancer
  • World
  • Product Initiative
  • GASTRIC CANCER - PIPELINE BY MAXIVAX SA
  • GASTRIC CANCER - PIPELINE BY AMBRX INC

TABLE ##: GASTRIC CANCER - PIPELINE BY ALTEOGEN INC AMBRX INC (AMBRX) IS A BIOPHARMACEUTICAL COMPANY WHICH FOCUSES ON THE DISCOVERY AND DEVELOPMENT OF PROTEIN-BASED MEDICINES BY USING ITS EXPANDED GENETIC CODE.

  • Gastric Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Product Initiative
  • 1.3 STAGES

Genetic syndromes inherited from a person' s parents such as hereditary are also known to cause gastric cancer.

  • Gastric Cancer
  • United States
  • World
  • Market Size
  • Merck & Co., Inc.
  • Gastric Cancer, Tumor, Node and Metastasis
  • The Case for Innovation

Gastric Breast Cancer; ##(##): ##-##.

  • Cancer
  • Gastric Cancer
  • Pathology
  • United States
  • Deals & Alliance
  • Clinical Trial profile. 1592 Trial Title
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Gastric Cancer
  • Therapy
  • World

From 2008 to 2010, Dr Greig was also President of SR One, GSK' s Corporate Venture Group.

  • Gastric Cancer
  • Genomics
  • Spain
  • Company
  • Oryzon Genomics S.A.